PL3532457T3 - Postacie krystaliczne hydroksynorketaminy - Google Patents
Postacie krystaliczne hydroksynorketaminyInfo
- Publication number
- PL3532457T3 PL3532457T3 PL18758671T PL18758671T PL3532457T3 PL 3532457 T3 PL3532457 T3 PL 3532457T3 PL 18758671 T PL18758671 T PL 18758671T PL 18758671 T PL18758671 T PL 18758671T PL 3532457 T3 PL3532457 T3 PL 3532457T3
- Authority
- PL
- Poland
- Prior art keywords
- hydroxynorketamine
- crystalline forms
- crystalline
- forms
- Prior art date
Links
- CFBVGSWSOJBYGC-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCC(O)C1=O CFBVGSWSOJBYGC-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1712304.3A GB201712304D0 (en) | 2017-07-31 | 2017-07-31 | Synthetic methods |
| GBGB1715010.3A GB201715010D0 (en) | 2017-09-18 | 2017-09-18 | Crystalline forms |
| GBGB1715500.3A GB201715500D0 (en) | 2017-09-25 | 2017-09-25 | Crystal forms of therapeutic compounds and dosage forms thereof |
| PCT/GB2018/052193 WO2019025792A1 (en) | 2017-07-31 | 2018-07-31 | CRYSTALLINE FORMS OF HYDROXYNORKETAMINE |
| EP18758671.4A EP3532457B1 (en) | 2017-07-31 | 2018-07-31 | Crystalline forms of hydroxynorketamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3532457T3 true PL3532457T3 (pl) | 2020-10-19 |
Family
ID=63294366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18758671T PL3532457T3 (pl) | 2017-07-31 | 2018-07-31 | Postacie krystaliczne hydroksynorketaminy |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11377416B2 (pl) |
| EP (1) | EP3532457B1 (pl) |
| JP (1) | JP2020529445A (pl) |
| CN (1) | CN111201217A (pl) |
| AU (1) | AU2018311307B9 (pl) |
| CA (1) | CA3071491A1 (pl) |
| ES (1) | ES2797381T3 (pl) |
| PL (1) | PL3532457T3 (pl) |
| WO (1) | WO2019025792A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110343050B (zh) * | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| WO2021101867A1 (en) * | 2019-11-18 | 2021-05-27 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Salts of (2r, 6r)-hydroxynorketamine, their crystal forms, and methods of making the same |
| US20230331655A1 (en) * | 2020-08-27 | 2023-10-19 | University Of Maryland, Baltimore | Hydroxynorketamine compounds and methods of use thereof |
| CN112521357B (zh) * | 2020-08-31 | 2021-10-08 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817699A (en) | 1997-05-30 | 1998-10-06 | Flores; John A. | Process for the preparation of ketamine ointment |
| KR100467669B1 (ko) * | 2002-08-21 | 2005-01-24 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| EP2766339B1 (en) * | 2011-10-14 | 2021-06-09 | The United States Of America, as represented by the Secretary, Department of Health & Human Services | The use of (2r, 6r)-hydroxynorketamine and other stereoisomeric hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| EP2948135B1 (en) | 2013-01-25 | 2019-01-02 | Case Western Reserve University | Compositions and methods for the treatment of pervasive development disorders |
| WO2015108985A1 (en) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| CN115521217A (zh) | 2014-11-04 | 2022-12-27 | 阿莫萨治疗公司 | 神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法 |
| JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| WO2016186968A1 (en) | 2015-05-15 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating motor disorders |
| EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| US11111210B2 (en) | 2015-11-18 | 2021-09-07 | Spirify Pharma Inc. | Phenyl cyclohexanone derivatives and methods of making and using them |
| EP3442940A1 (en) | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| US20190380978A1 (en) | 2016-06-03 | 2019-12-19 | Small Pharma Ltd | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof |
| CN110035997A (zh) | 2016-09-16 | 2019-07-19 | 生物制药沃克斯有限公司 | 羟基去甲氯胺酮前药 |
| IL315066A (en) | 2016-10-27 | 2024-10-01 | Univ Chiba Nat Univ Corp | Application of (s)-norketamine and salt therof as pharmaceutical |
| ES2991544T3 (es) * | 2016-11-30 | 2024-12-04 | Wolfson Philip E | Ketamina para el tratamiento de síntomas relacionados con la menstruación |
| ES2924188T3 (es) | 2017-09-25 | 2022-10-05 | Small Pharma Ltd | Formas sólidas de dosificación oral de derivados de ketamina |
-
2018
- 2018-07-31 CN CN201880063777.9A patent/CN111201217A/zh active Pending
- 2018-07-31 CA CA3071491A patent/CA3071491A1/en active Pending
- 2018-07-31 ES ES18758671T patent/ES2797381T3/es active Active
- 2018-07-31 JP JP2020506258A patent/JP2020529445A/ja active Pending
- 2018-07-31 AU AU2018311307A patent/AU2018311307B9/en active Active
- 2018-07-31 EP EP18758671.4A patent/EP3532457B1/en active Active
- 2018-07-31 WO PCT/GB2018/052193 patent/WO2019025792A1/en not_active Ceased
- 2018-07-31 US US16/635,406 patent/US11377416B2/en active Active
- 2018-07-31 PL PL18758671T patent/PL3532457T3/pl unknown
-
2022
- 2022-05-27 US US17/804,338 patent/US20220306569A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2797381T3 (es) | 2020-12-02 |
| CN111201217A (zh) | 2020-05-26 |
| EP3532457B1 (en) | 2020-03-18 |
| US11377416B2 (en) | 2022-07-05 |
| CA3071491A1 (en) | 2019-02-07 |
| US20200157040A1 (en) | 2020-05-21 |
| WO2019025792A1 (en) | 2019-02-07 |
| JP2020529445A (ja) | 2020-10-08 |
| AU2018311307B2 (en) | 2021-08-12 |
| US20220306569A1 (en) | 2022-09-29 |
| AU2018311307B9 (en) | 2021-09-09 |
| AU2018311307A1 (en) | 2020-02-13 |
| EP3532457A1 (en) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273730A (en) | crystalline forms | |
| SG10201913200XA (en) | Crystalline form of lorlatinib free base | |
| PL3577125T3 (pl) | Postacie krystaliczne alafenamidu tenofowiru | |
| ZA201906464B (en) | Crystalline forms of (s)-afoxolaner | |
| IL246385A0 (en) | Crystalline forms of efitinib di-malate | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| SI3380554T2 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| PL3113773T3 (pl) | Krystaliczne postaci grapiprantu | |
| HUE066360T2 (hu) | Eravaciklin kristályformái | |
| SG10202101979TA (en) | Crystalline forms of c21h22ci2n4o2 | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| IL269073A (en) | Crystalline forms of obeticholic acid | |
| IL265445A (en) | crystalline forms | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| GB201518589D0 (en) | Crystalline form of tetraacetylethylenediamine | |
| IL270937A (en) | Crystalline forms of saltalicib | |
| ZA201902553B (en) | Crystalline forms | |
| GB201715010D0 (en) | Crystalline forms | |
| HK40025092A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
| GB201721386D0 (en) | Chrondogy of time-wave | |
| HK40014545A (en) | Crystalline forms of (s)-afoxolaner |